MNKD
What one share of Mannkind holds
Pharmaceutical Preparations
We are a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Mannkind’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.28 |
|---|---|
| Profit | −$0.14 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$0.06 |
| Cash and investments | $0.17 |
| Debt | $1.03 |
| Book value | −$0.22 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.90 | $1.36 | $0.01 | −$0.86 | — | −$1.92 |
| 2017 | $0.11 | −$1.13 | — | −$0.62 | — | −$1.80 |
| 2018 | $0.19 | −$0.60 | $0.00 | −$0.26 | — | −$0.94 |
| 2019 | $0.32 | −$0.27 | $0.01 | −$0.47 | — | −$0.90 |
| 2020 | $0.29 | −$0.26 | $0.00 | −$0.13 | — | −$0.75 |
| 2021 | $0.30 | −$0.32 | $0.05 | −$0.29 | — | −$0.83 |
| 2022 | $0.39 | −$0.34 | $0.03 | −$0.34 | — | −$0.95 |
| 2023 | $0.75 | −$0.04 | $0.16 | −$0.03 | — | −$0.91 |
| 2024 | $1.01 | $0.10 | $0.03 | $0.12 | — | −$0.26 |
| 2025 | $1.11 | $0.02 | $0.01 | $0.04 | — | −$0.17 |